Parapyruvate, an Impurity in Pyruvate Supplements, Induces Senescence in Human Fibroblastic Hs68 Cells via Inhibition of the α-Ketoglutarate Dehydrogenase Complex.
Level 5 - mechanism / opinion, no new human data
In vitro cell culture and biochemical assay with no human clinical data
PubMed 29931974 · doi:10.1021/acs.jafc.8b01138
What was done
Researchers synthesized pure parapyruvate (99.8 ± 0.1% purity) to test its inhibition of the α-ketoglutarate dehydrogenase complex (KGDHC) and its ability to trigger cellular senescence in human fibroblastic Hs68 cells in vitro. They examined whether adding calcium ions (a KGDHC activator) could counter the effect, and quantified parapyruvate impurity concentrations across five commercial brands of calcium pyruvate dietary supplements.
What was found
Parapyruvate dose-dependently reduced KGDHC activity with an IC50 of 4.13 mM and induced senescence in Hs68 fibroblasts. Calcium ions antagonized these pro-senescent effects. Parapyruvate content in the five tested commercial calcium pyruvate supplement brands ranged from 1.4 ± 0.1% to 10.6 ± 0.2%.
Why it matters
Calcium pyruvate supplements frequently contain parapyruvate as an unlisted manufacturing impurity. These findings demonstrate that parapyruvate impairs mitochondrial enzyme function and drives cellular aging pathways in human cells, raising potential safety and regulatory concerns for these supplements.
Limits
The investigation was restricted to in vitro assays and a single human cell line; in vivo bioavailability, tissue distribution, and actual clinical toxicity in humans were not evaluated. Only five supplement brands were surveyed, and specific quantitative markers of senescence were not detailed in the abstract.
Cited by
- supports Pyruvate degrades spontaneously in aqueous solution, forming toxic degradation products.